SCHEMBL2128047

SCHEMBL2128047

N=C(NO)c1ccc2nc(-c3cccc(Cl)c3)cn2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 5/20 0.48
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
MAPT P10636 3/20 0.48
ALDH1A1 P00352 9/20 0.47
KDM4E B2RXH2 6/20 0.47
LMNA P02545 3/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
HPGD P15428 4/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
PKM P14618 1/20 0.46
STAT3 P40763 1/20 0.46
STAT1 P42224 1/20 0.46
ALDH1A3 P47895 2/20 0.45
KCNH2 Q12809 2/20 0.45
CYP2C9 P11712 1/20 0.45
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947124 0.86 RAB9A (0.49) NR4A2NPC1RAB9AMAPTALDH1A1
SCHEMBL4951858 0.80 ALDH1A1 (0.53) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL2128768 0.80 RAB9A (0.75) NR4A2NPC1RAB9AMAPTALDH1A1
Hydrochloric Acid SCHEMBL4952786 0.79 ALDH1A1 (0.52) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL2127100 0.78 NPC1 (0.60) NPC1RAB9AMAPTALDH1A1KDM4E
SCHEMBL8468965 0.78 NR4A2 (0.54) NR4A2NPC1RAB9AMAPTALDH1A1
SCHEMBL2128050 0.78 NR4A2 (0.54) NR4A2NPC1RAB9AMAPTALDH1A1
SCHEMBL2127099 0.78 NPC1 (0.66) NR4A2NPC1RAB9AMAPTALDH1A1
SCHEMBL2126828 0.77 ALDH1A3 (0.55) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL21708017 0.76 NPC1 (0.65) NPC1RAB9AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US claimed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP claimed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US claimed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP claimed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO claimed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP claimed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 NR4A2 286/4885NPC1 2959/4885RAB9A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.